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Abstract: Cancer “stem cells” (CSCs) sustain the hierarchies of dividing cells that characterize can-
cer. The main causes of cancer-related mortality are metastatic disease and relapse, both of which 
originate primarily from CSCs, so their eradication may provide a bona fide curative strategy, 
though there maybe also the need to kill the bulk cancer cells. While classic anti-cancer chemother-
apy is effective against the dividing progeny of CSCs, non-dividing or quiescent CSCs are often 
spared. Improved anti-cancer therapies therefore require approaches that target non-dividing CSCs, 
which must be underpinned by a better understanding of factors that permit these cells to maintain 
a stem cell-like state. During hematopoiesis, retinoic acid receptor (RAR) γ is selectively expressed 
by stem cells and their immediate progeny. It is overexpressed in, and is an oncogene for, many 
cancers including colorectal, renal and hepatocellular carcinoma, cholangiocarcinomas and some 
cases of acute myeloid leukemia that harbor RARγ fusion proteins. In vitro studies suggest that 
RARγ-selective and pan-RAR antagonists provoke the death of CSCs by necroptosis and point to 
antagonism of RARγ as a potential strategy to treat metastatic disease and relapse, and perhaps 
provide a cure for some cancers. 
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1. Introduction 
The stem cell theory of cancer states that most, if not all, cancers arise from a tissue-
specific stem cell [1]. When an oncogenic insult modifies one of the stem or progenitor 
cells that give rise to various types of mature tissue cells, it converts it into a cancer-initi-
ating cell. This cell is the origin of cancer, but more changes are needed before it, or an 
offspring of the cancer-initiating cell, becomes a cancer stem cell (CSC) [2]. This cell sus-
tains the hierarchy of dividing cells that characterizes cancer. 
Classic anti-cancer chemotherapy is effective against the dividing progeny of CSCs, 
but spares non-dividing CSCs. As early as 1999, a rare and quiescent subpopulation of 
primitive leukemia cells was isolated from samples from 6 patients with chronic-phase 
chronic myeloid leukemia (CML). These leukemia stem cells (LSCs) were insensitive to 
even high doses of cytotoxic agents targeted against the cell cycle [3]. CML LSCs have also 
been found to be resistant in vitro to the tyrosine kinase inhibitors, such as imatinib, that 
are used to treat CML and many different types of cancer [4,5]. LSCs are envisaged to be 
insensitive to imatinib in vivo. Curing CML patients is also very challenging because LSCs 
that are resistant to treatment can lead to disease relapse following remission, and even 
after allogeneic transplantation [6]. Accordingly, relapse is the main cause of leukemia-
related mortality. 
CSCs are also largely the cause of carcinoma metastases. Whilst cancer treatment has 
made great strides in the last 40 years, the treatment of relapsed and metastatic disease 
has not advanced significantly. A view of clinicians is that once a cancer has progressed 
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to metastatic disease it is often beyond successful treatment by conventional chemothera-
peutics. For example, stage 4 metastatic colorectal cancer (CRC) is considered terminal, 
with the 5-year survival being 5% for men and 10% for women. Finding a way to eradicate 
CSCs will undoubtable reduce cancer mortality in today’s world. The era of the COVID-
19 pandemic has thrown this effort into sharp relief, with severe disruption in cancer 
screening, diagnosis and elective surgery. This scenario is anticipated to lead to an in-
crease in untreatable cancers and premature deaths. The development of new therapies 
that are capable of targeting CSCs to avoid and treat aggressive and metastatic disease is 
therefore a priority. There may also be the need to kill the bulk of the cancer cells that are 
the progeny of CSCs and that kill the patient. Therapies targeted to CSCs may also kill 
non-CSC cells or be effective also against the latter cells due to the exhaustion of CSCs. 
Alternatively, anti-CSCs agents will be used in conjunction with chemotherapeutics to 
deal with the cancer burden. To achieve the targeting of CSCs, identification of oncogenic 
events within CSCs is critical. Here, we examine evidence that supports the view that 
RARγ is an Achilles heel for some cancers. 
2. The Concept of the Cancer Stem Cell 
Evidence in support of the concept of CSCs is underpinned by investigative studies, 
in particular in acute leukemias that led to the characterization of LSCs. The first step 
towards the identification of LSCs was the demonstration that the cells from patients with 
acute myeloid leukemia (AML) are a hierarchy of cancer cells that parallel the well-de-
scribed development of cell lineages during normal hematopoiesis [7,8]. Cells from AML 
patients formed colonies in vitro in the colony forming assay that is used to describe the 
various developmental stages of normal bone marrow cells [9]. The identity of the cells 
giving rise to the AML colony-forming units (AML-CFU) was determined by using mon-
oclonal antibodies to cell surface antigens and complement to lyse cells from a number of 
patients followed by the use of the colony-forming assay [10]. AML-CFU were phenotyp-
ically distinct from patients’ bulk blast cell populations and classified as similar to (i) prim-
itive and pluripotent normal colony forming units from normal bone marrow, (ii) early 
granulocyte/macrophage lineage-committed colony-forming units, and (iii) late granulo-
cyte/macrophage lineage-committed colony-forming units. 
When assayed using 3D and co-culture techniques, human hematopoietic stem cells 
(HSC) and primitive progenitors (Long-Term Culture Initiating cells, LTC-IC), display 
similar phenotypes, which are distinct from normal colony-forming progenitors [11]. 
Even so, HSC are truly defined by their ability to reconstitute hematopoiesis in the severe 
combined immunodeficient (SCID) mouse [12] and subsequent models [13]. It was thus 
predicted that AML “stem cells” would share these characteristics and have the ability to 
engraft upon transplantation into SCID mice. This was indeed the case, and leukemia en-
graftment in SCID mice was observed for cells from most AML subtypes, with the excep-
tion of acute promyelocytic leukemia (APL) [14]. The frequency of AML cells that en-
grafted was very low, at around 1 per 106 cells, and much lower than the frequency of 
AML-CFU within patients’ cells, at 1 in 100. Moreover, leukemias could also only be en-
grafted in mice using primitive CD34+CD38- cells, whereas AML-CFU were most preva-
lent in the CD34+CD38+ cell population. The primitive leukemia cells that could be en-
grafted were termed SCID leukemia-initiating cells and, in essence, are AML “stem cells”. 
While the characterization of cells within solid tumors that possess a stem cell phe-
notype is less advanced than for the leukemias, CSCs for various carcinomas have been 
described (reviewed in [15]), including those for colorectal cancer (CRC) [16], breast can-
cer (BC) [17], brain cancer [18], head and neck squamous cell carcinoma [19], melanoma 
[20,21] and pancreatic cancer [22]. Similar to AML, these populations of cells may engraft 
efficiently in mice, including by a single CSC in the case of melanoma. The proportion of 
CSCs within a tumor varies, ranging from very few cells to up to 25%, and this large dif-
ference probably relates to the nature of the different types of cancer. As to whether car-
cinoma CSCs are bona fide, gene expression profiling has shown that they express 
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stem/progenitor associated genes. The presence and/or predominance of CSCs is im-
portant to the outcome from treatment. For example, brain CSCs are resistant to radiation 
in vitro and in vivo, due to activation of the DNA damage response [23]. In the case of BC, 
analysis of 186 genes differentially expressed by BC CSCs compared with normal breast 
epithelium has led to the identification of an “invasiveness” signature associated with risk 
of metastasis and death [24]. 
3. Targeted Therapies for Cancer 
The ongoing focus in the endeavor to develop new cancer treatments is the design of 
drugs that are targeted to a specific type of cancer, to personalize treatment and extend 
the realm of conventional chemotherapeutics [25]. As to the significance of LSCs/CSCs for 
disease outcome, whether the new treatments that are developed adversely affect 
LSCs/CSCs is a critical consideration. In the case of AML, LSCs are resistant in vitro to 
daunorubicin [26] and to Arc-C [27]. The cell surface receptor fms-like tyrosine kinas 3 
(Flt3) has been used to identify HSCs and progenitor cells [28]. Flt3 is a class III tyrosine 
kinase that has structural homology to the c-kit and macrophage colony-stimulating factor 
(CSF1) receptors. Expression in humans is restricted to CD34+ bone marrow cells which 
includes HSCs [29]. Recent in vivo studies have revealed an instructive role for the ligand 
for Flt3 whereby it drives multipotent hematopoietic progenitor cells towards the mye-
loid/lymphoid and away from the megakaryocyte/erythroid lineages [30]. As an approach 
to treating AML, Flt3 mutations, that occur in 30% of case, have been targeted by the use 
of small molecule tyrosine kinase inhibitors that are effective against Flt3. However, and 
so far, the early use of the inhibitors has met with modest success. As to the outcomes 
from early trials. there have been just short-lived responses of peripheral blast cells and 
bone marrow blast cells have responded less frequently [31]. Antibodies to Flt3 might 
provide another way of targeting Flt3, to inhibit signaling, to treat AML. There are now 
new-generation Flt3 inhibitors that are more specific, more potent and less toxic. Even so, 
acquired resistance to inhibitors remains a challenge and very low 5-year survival levels 
from first relapse of around 10% underline the urgent need for new treatments [32]. 
Perhaps the most successful example to date of a precision medicine approach that 
efficiently targets cancer stem cells is the use of all-trans retinoic acid (ATRA)-based ther-
apy to treat APL [33]. APL, which is classified as M3 under the French-American-British 
(FAB) system, accounts for between 5–15% of total cases of AML. The most common form 
of APL, characterized by the t(15;17)(q24;q21) translocation leading to the creation of a 
fusion between the PML and RARA (retinoic acid receptor) genes. While APL is cytoge-
netically a less complex disease compared with non-APL AML, it is similarly defined by 
a hierarchy of cancer cells as evidenced by the presence of the oncogenic PML-RARα fu-
sion protein in patients’ LSCs [34]. For APL, ATRA in combination with arsenic trioxide 
induces differentiation and LSC clearance, which is curative in over 95% of patients 
[35,36]. Therapeutic ATRA treatment (10−6 M) does not significantly affect normal hema-
topoiesis but instead targets the oncogenic PML-RARα fusion protein, promoting disas-
sociation of transcriptional co-repressors from both PML-RARα and wild type RARα as 
well as their proteolytic degradation to drive differentiation and apoptosis. In vitro stud-
ies using the APL-like NB4 cell line have identified a role for aberrant histone acetylation 
to chromatin in the pathogenesis of this disease, which was relieved by ATRA treatment 
[37]. Furthermore, the combination of ATRA and arsenic trioxide induced greater demeth-
ylation of target genes in APL cells, which may be important for lasting differentiation 
and remission [38]. Underscoring the importance of epigenetics, recent research in non-
APL AML has suggested that epigenetic reprogramming of genes involved in differenti-
ation, proliferation and survival effectively sensitizes LSC to ATRA-based therapy [39,40]. 
In the case of solid tumors, such as head and neck, ATRA targets CSCs to drive apoptosis 
and there is an impact on tumor control when combined with radiotherapy [41]. 
The requirement for the development of new therapeutic approaches is equally 
pressing for solid tumors. For solid tumors, a general therapeutic approach is to prevent 
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the growth of new blood vessels that feed the tumor. As mentioned above, the prognosis 
of stage 4 metastatic CRC is very poor and the 5-year survival for metastatic prostate car-
cinoma (PCa) is ~29%. Vascular endothelial growth factor (VEGF) promotes tumor angi-
ogenesis and two different approaches to target VEGF have been investigated and evalu-
ated in clinical trials. Firstly, direct targeting of VEGF-A by bevacizumab (Avastin), a hu-
manized monoclonal antibody [42], and secondly, enzymatic inhibition of VEGF receptor 
tyrosine kinase activity using vatalanib [43]. The addition of bevacinzumab to chemother-
apy and its use in other combinatorial strategies has been demonstrated to improve sur-
vival and it now a standard addition to frontline treatment of advanced CRC and repre-
sents key therapeutic approach in cancer [42]. Development of vatalanib, on the other 
hand, was discontinued due toxicity issues [44]. Whilst excessive abnormal angiogenesis 
is important to solid tumor progression, an alternative view is that promotion of vessel 
maturation, rather than to ablate vessels, could reduce tumor hypoxia and improve drug 
uptake [45]. 
In PCa, targeted approaches have focused on androgen-deprivation in combination 
with chemotherapy or radiotherapy [46,47]. Unfortunately, a highly aggressive and met-
astatic hormone-independent form of the disease (castration or hormone-resistant pros-
tate cancer) develops in a significant fraction of patients receiving treatment, leading to 
treatment failure. Treatment options for these patients are extremely limited and even 
with the introduction of better therapeutics, the average survival time of patients with 
hormone-resistant PCa is still often less than 36 months [46,47]. Presently, investigators 
are looking to delineate the androgen signaling pathways in PCa to develop new treat-
ments [48]. 
4. RARγ Is a Fundamental Control on Stem Cell Behavior 
There are three retinoic acid receptor (RAR) isotypes (RARα, RARβ, RARγ) that het-
erodimerize with retinoid X receptors (RXRα, RXRβ, RXRγ) and bind to retinoic acid re-
sponse elements (RAREs). Upon binding their physiological ligand, all-trans retinoic acid 
(ATRA), undergo coregulator exchange to activate target genes and modify cell behavior. 
It is well known that an appropriate level of ATRA is crucial to the conduct of normal 
embryonic development [49]. In this regard, the distribution and levels of ATRA in em-
bryonic tissue is very tightly regulated [50]. Various mechanisms guard against dysregu-
lated ATRA synthesis and metabolism [51]. ATRA also plays a crucial role in the differ-
entiation of embryonic stem cells, with both classical genomic effects and non-genomic 
events, such as the activation of kinase cascades, playing a role [52]. Additionally, the 
RARα and RARγ regulatory networks within cells are highly extensive, as revealed by 
integrative genomics dissection of the differentiation of F9 embryonal stem cells [53]. 
Therefore, perturbations to the control of cell behavior by RARs might be expected to un-
derlie the abnormal behavior of some cancer cells, and, as below, this is indeed the case. 
RARs are key regulators of gene expression within stem cells, with the RARα and 
RARγ isotypes playing critical and opposing roles in hematopoiesis. RARγ is selectively 
expressed in hematopoietic stem cells (HSCs) and their immediate progeny (Lineage−ve, 
Sca-1+ve, c-Kit+ve (LSK)), and its activation by ATRA is vital for the maintenance of HSC 
numbers. Rarg knockout mice display markedly reduced numbers of HSCs with a con-
comitant increase in more mature progenitors [54]. By contrast, RARα-mediated tran-
scription drives neutrophil differentiation of myeloid progenitors. It is important to bear 
in mind that evidence strongly suggests the activities of both RARα and RARγ are regu-
latory, rather than obligatory, for myeloid cell development, which persists in mice in the 
context of knockouts of Rara and Rarg. The roles of RARα and RARγ are also linked to 
other controls on myeloid differentiation. The cytokine granulocyte colony-stimulating 
factor (G-CSF) is important to myelopoiesis and RAR-regulated cellular events interact 
with signaling from the G-CSF receptor (G-CSFR) [55]. Similar to RARs, G-CSFR is dis-
pensable, and can therefore be considered regulatory. However, in mice lacking G-CSFR, 
cellular expansion associated with granulopoiesis fails to occur, a phenotype that is also 
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displayed upon treatment with the pan-RAR antagonist AGN19430 [56]. We can therefore 
conclude that both RARα and RARγ are critical for the proper conduct of hematopoiesis, 
at least, whereby they promote cell differentiation and self-renewal, respectively. The 
crosstalk between RARs and G-CSFR is an intriguing aspect of the functionality of RARs 
and it is likely that other examples remain to be identified. 
Findings from studies of zebrafish development further support the view that RARγ 
activity is important for the maintenance of stem/progenitor cell populations [57]. In 
zebrafish, there are two major RAR isotypes, RARα and RARγ, and treatment of zebrafish 
embryos four hours post-fertilization with the RARγ-selective agonist AGN205327 
blocked the development and growth of tissues that are derived from cranial neural crest 
and primitive mesoderm. Somite formation and axial length were reduced, and the for-
mation of cranial bones and anterior neural ganglia that arise from the cranial neural crest 
was disrupted. AGN205327 treatment also blocked pectoral fin outgrowth and caudal fin 
regeneration after transection. The lateral plate mesoderm stem/progenitor cells associ-
ated with pectoral fin tissue were intact as evidenced by the presence of pectoral fin buds 
and Tbx-5 positive immunostaining. Moreover, the AGN205327-dependent block of pec-
toral fin development was reversed by co-treatment with an RARγ-selective antagonist 
AGN205728, or by RARγ agonist washout. Thus, RARγ supports a stem cell phenotype 
by actively blocking development and differentiation. 
Various findings from studies of mouse embryonal stem cells point towards RARγ 
influencing the lineage fate of stem cells. F9 embryonal carcinoma cells lacking both alleles 
of Rarg display diminished expression of genes that are central to cell fate determination 
such as Hoxa1 [58], which patterns the hindbrain and craniofacial features during embry-
onic development. Within F9 embryonal carcinoma cells, Rar/Rxr dimers specifically in-
teract with genomic regions that are associated with pluripotency, as characterised by 
binding of pluripotency-associated transcription factors [59]. Chromatin structure is inti-
mately connected with cell pluripotency and findings from studies of mouse Rarg knock-
out embryonic stem cells have revealed that active Rarγ plays a role in ATRA-induced 
chromatin remodelling [60]. In embryonic stem cells, Rarγ signalling is essential for the 
expression of most of the ATRA-regulated transcriptome, including the transcription fac-
tor Meis1 (myeloid ecotropic viral integration site-1). Meis1 expression was observed to 
be increased when wild type (WT), but not Rarg knockout (Rarg−/−), cells were treated with 
ATRA. In WT, but not in Rarg−/− cells, there was also a rapid increase in the transcription-
ally permissive epigenetic markers, histone H3 acetylated Lys9/Lys14 (K9Ac/K14Ac), at sites 
downstream and proximal to transcription start site of Meis1. In other words, loss of Rarγ 
prevented ATRA-driven epigenetic changes at the Meis1 gene. The means by which Rarγ 
can provoke changes to the epigenetic signature remain unclear because RAREs are not 
present, nor was Rarγ binding detected in either the downstream or proximal regions of 
the Meis1 promoter. 
The above evidence strongly suggests that RARγ is a key regulator of the behaviour 
of stem cells. There are two possibilities regarding how RARγ might have an oncogenic 
role within stem cells and/or their progeny. First, overexpression might have a direct ac-
tion to dysregulate the expression of key target genes and, in turn, change cell behaviour. 
Alternatively, it is important to bear in mind that RARγ provokes epigenetic changes 
within stem cells and that epigenetic signatures are increasingly considered as important 
to cancer, cell responsiveness to chemotherapeutics, and targeting therapeutic interven-
tions. Some oncogenes influence the fate of stem cells: LMO2, BCR-ABLp190, and BCR-
ABLp210 are specifically associated with and drive human T acute lymphoblastic, B acute 
lymphoblastic leukemia, and chronic myeloid leukemia (CML), respectively. When the 
expression of each of these oncogenes was restricted to HSCs in transgenic mice, each 
oncogene led to the respective human-like lineage-restricted leukemia [61–63]. It seems, 
therefore, that that each oncogene had set the choice of the targeted leukemia stem cell 
(LSCs), as well as their progeny, towards a distinct developmental pathway. The different 
global patterns of DNA methylation at promoters for LSCs from each of the mice led the 
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investigators to conclude that the tumor stem cell priming, to fix the lineage fate of the 
leukemia cells, was primarily due to epigenetic control. Similarly, different mutant 
RUNX1 oncoproteins, which are drivers of some case of acute myeloid leukemia, were 
also observed to program distinct HSC lineage trajectories, skewing cells towards either a 
B cell or megakaryocyte/erythroid identity. The different mutant proteins were also ob-
served to alter lineage-specific chromatin priming [64]. Another aspect to the importance 
of epigenetics in leukemia is the role of DNA methytransferases alongside ATRA in the 
regulation of expression Hox genes, which are critical for the proper maintenance of HSC, 
as well as proliferation and survival of LSC [65]. 
5. RARγ Is an Oncogene for Some Cancers 
Recent discoveries are that RARγ is a molecular driver of the cancers summarized in 
Table 1, and overexpression occurs other than in AML whereby RARγ fusion proteins are 
seen in a rare subtype of AML. 
As outlined above, the roles of RARA-associated gene rearrangements in the patho-
physiology of APL have been well-characterized and patients are cured by the use of 
ATRA with arsenic trioxide [36]. Recently, cases of APL that are characterized by rear-
rangements of the RARG gene rather than the RARA gene have been identified [66]. Here, 
among nine patients, fusions were observed between the RARG gene and the genes for 
NUP98 (3 patients), CPSF6 (4 patients), NPM1 (1 patient) and PML (1 patient). The mech-
anisms underlying the transformations by the fusion proteins remain to be established. 
The NUP98 (nucleoporin) N-terminal region acts as a transcription activator, CPSF6 is 
subunit of cleavage factor 1 (an RNA binding protein), NPM1 (nucleophosmin) is a nucle-
olar protein that participates in chromatin modelling, and PML is a tumor suppressor 
protein. With the exception of the patient harboring the PML-RARG translocation, all the 
other cases with RARG gene rearrangements failed to respond to ATRA-based therapy. 
For patients with RARG gene rearrangements there is therefore the need for new treat-
ment strategies. 
Table 1. Over and aberrant expression of RARγ in human cancers. 
Malignancy RARγ Expression Impact on Disease 
Acute myeloid leukemia RARγ chimeric protein Not responsive to retinoid-based therapy 
Colorectal carcinoma Overexpression Resistance to chemotherapeutics 
Cholangiocarcinoma Overexpression Poor prognosis and drug resistance 
Hepatocellular carcinoma Overexpression Promotes growth of xenografts 
Renal cell carcinoma Overexpression May contribute to disease progression 
The potential impact of RARγ on disease progression in AML was brought to atten-
tion by a case of AML that was characterized by a novel t(4;15) (q31;q22) translocation 
involving the TMEM154 and RASGRF1 genes. Here, a 30-year-old woman with relapsed 
AML was treated for eight days with ATRA as part of investigational study but died with 
rapid disease progression. Primary AML cells taken from the patient proliferated rapidly 
when treated ex vivo with ATRA, as well as isotype-selective agonists of RARα and 
RARγ, and there was an increase in the levels of nuclear RARγ upon ATRA treatment. 
Whilst requiring further investigation, the basis of the growth-stimulatory response to 
ATRA could be associated with the increase in the level of RARγ within the nucleus fol-
lowing ATRA treatment [67]. 
RARγ is frequently overexpressed in human CRC [68], cholangiocarcinoma (CCA) 
[69] and hepatocellular carcinoma (HCC tissues) [70]. 73% of CRCs overexpress RARG 
mRNA and protein compared with 20% for adjacent non-tumor colorectal tissue (20%). 
CRC cell lines, such as HT29, HCT116, RK0 and SW480, also overexpress RARγ and 
knockdown of RARG enhanced the sensitivity of CRC cells lines to the chemotherapeutic 
drugs 5-fluorouracil, oxaliplatin and vincristine sulphate. Additionally, the level of the 
Int. J. Mol. Sci. 2021, 22, 3632 7 of 14 
 
 
multidrug resistance protein 1 (MDR1) was diminished in knockdown cells alongside 
suppression of the Wnt/β-catenin pathway [68]. Chemo-resistant bile duct carcinoma 
CCA is the second most common hepatic malignancy and RARγ overexpression is asso-
ciated with a poor prognosis and resistance to 5-flurouracil [69]. In agreement with these 
findings, RARγ interacted with β-catenin in CCA cells, leading to its nuclear translocation. 
Furthermore, shRNA-mediated knockdown of RARγ reduced proliferation, migration 
and invasion in vitro, and xenograft engraftment in vivo. 
In HCC, overexpression of RARγ is found in the majority of primary tissues as well 
as HCC cell lines. In HepG2 HCC cells, overexpression RARγ promoted colony formation 
and xenograft engraftment [70]. Further evidence for a role for RARγ in HCC is the find-
ing that in the SMMC-7721 cell line, expression of microRNA-30a-5p (which has been 
shown to downregulate RARG, manuscript in preparation) suppressed the proliferation 
and invasion [71]. Additionally, in clear cell renal cell carcinoma (ccRCC), around 50% of 
tissues overexpress RARγ [72], which may contribute to disease progression. 
While both PCa cells and normal prostate epithelium express RARα and RARγ to-
gether, in the case of PCa, the tumor cells appear to be dependent on active RARγ for their 
proliferation and survival. The level of ATRA in primary PCa tissues is close to the limit 
of detection (at approximately 1 ng/gram tissue), whereas in adjacent normal tissues and 
benign prostate hyperplasia levels up to 8 times greater are found [73]. Results from 
LNCaP PCa cells suggest this scenario will confer dependency on the action of RARγ. This 
is because a 0.24 nM concentration of ATRA (equivalent to 1 ng/gram tissue) is sufficient 
to transactivate RARγ but not RARα, which requires a higher concentration of 19.3 nM 
ATRA (Figure 1). 
 
Figure 1. Prostate cancer tissue is adapted to grow in sub-nanomolar concentrations of ATRA. 
Adjacent normal cells and benign prostate hyperplasia cells see ~8 times more ATRA than level 
within patients’ PCa tissue which is close to the level of detection at ~1 ng/g tissue [28]. For pa-
tients’ PCa tissue, there is sufficient to transactivate RARγ, which requires just 0.24 nM ATRA (see 
Table 2). RARα requires 19.3 nM ATRA for transactivation (see Table 2) and therefore is unlikely 
to be active within patients’ PCa tissue. This figure was created using Servier Medical Art tem-
plates, which are licensed under a Creative Commons Attribution 3.0 Unported License; 
https://smart.servier.com; accessed on 28 February 2021. 
  
Int. J. Mol. Sci. 2021, 22, 3632 8 of 14 
 
 
Table 2. Antagonism of RARγ potently inhibits colony formation by prostate carcinoma cell lines. 
Compound 
Kd, nM IC50, nM 
RARα RARβ RARγ DU145 LNCaP PC3 
Pan-RAR antagonist (AGN194310) 4.3 5 2 34 16 18 
RARγ antagonist (AGN205728) 2400 4248 3 6 3 5 
RARβγ antagonist (AGN194431) 300 6 70 88 99 103 
RARα antagonist (AGN196996) 3.9 4036 >10 K 201 203 235 
Pan-RAR agonist (ATRA) ND ND ND 402 344 419 
The Kd values for affinity are for binding to baculovirus-expressed RARα, RARβ and RARγ DU145 and PC3 cells express 
RARα and RARγ and LNCaP cells express RARα, β and γ. IC50 values are the concentration of compound that inhibited 
plate colony formation by 50% by serum free (ITS+)-grown LNCaP, DU145 and PC3 cells. For the pan-RAR and RARγ-
selective antagonists, the IC50 values are close to the Kd values. 
6. Antagonising RARγ Kills Cancer Stem Cells 
The action of antagonists of RAR on multiple cancer types provides strong support 
to the notion that RARγ possesses oncogenic potential. Early studies investigated in PCa 
cell lines and primary cells the activity of the pan-RAR antagonist AGN194310, which has 
high affinities for RARα, β and γ (Table 2) but not retinoid X receptors. At an IC50 value 
of 16 nM, which is close to the Kd values for RARα, β and γ, AGN194310 treatment led to 
growth arrest and cell death of DU145, LNCaP and PC3 PCa cell lines cultured in flasks 
(which contain a high proportion of non-CSC-like cells) [74]. AGN194310 treatment also 
ablated colony formation (which is dependent on the activities of CSC-like cells) by PCa 
cell lines as well as the breast cancer cell lines MCF-7 and MDA-MB-213 (unpublished 
data). Similar results were observed for primary PCa cells but not normal prostate epithe-
lial cells, which were 50% less sensitive (discussed later) [74]. Thus, for both cell lines and 
primary cells, AGN194310 demonstrated efficacy against both CSC-like and non-CSC-like 
cells. 
The importance of RARγ activation for the survival of PCa CSC-like cells may explain 
why patient-derived PCa cells were more sensitive to AGN194310. This is because the 
bovine serum albumin (BSA)-supplemented medium used to culture patient-derived PCa 
cells and normal prostate epithelium when testing the pan-RAR antagonist AGN194310 
would likely contain a concentration of ATRA sufficient to activate RARγ but not RARα. 
This notion was further strengthened by experiments using highly selective antagonists 
for RARα and RARγ: AGN195183 and AGN205728, respectively (Table 2). Consistent 
with idea that RARα does not play a functional role in the maintenance of a stem cell 
phenotype in PCa cells, its antagonism had no effect. By contrast, when used at concen-
tration of 5 nM (IC50) (which is close to its Kd value), treatment with the RARγ-selective 
antagonist AGN205728 led to growth arrest and cell death in cell lines (which was syner-
gistic in combination with docetaxel). In agreement with the data from AGN194310, 
AGN205728 also inhibited the colony-forming potential of PCa [75] and breast cancer cell 
lines (unpublished data), again suggesting that both CSC-like and non-CSC-like cells were 
targeted. Confirming a survival-supportive role for RARγ within PCa cells, the RARγ-
selective agonist AGN205327, and also 0.1 nM ATRA (a concentration that activates only 
the RARγ isotype), both increased PCa colony formation. Non-tumorigenic RWPE-1 cells 
did not exhibit increased colony formation when treated in the same way. These findings, 
together with the identification of miR-30a-5p as a tumor suppressor in PCa [76], strongly 
support to the view that RARγ does indeed represent a potential Achilles heel for PCa. 
Tumors of the central and peripheral nervous system are the most common cause of 
cancer mortality in children and there is an urgent need to improve treatment options. 
Primitive neuroectodermal tumors (PNETs) include neuroblastoma, Ewing’s sarcoma, 
retinoblastoma, medulloblastoma and supratentorial primitive neuroectodermal tumors 
(stPNETs). Primary cells biopsied from these tumors will harbor specific genetic abnor-
malities (Figure 2a) but with nevertheless similar phenotypes. The culture of primary 
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PNET cells in Neurocult (a specialized serum-free neural stem cell medium, STEMCELL 
Technologies) supplemented with 20 ng/mL epidermal growth factor, leads to the for-
mation of neurosphere-like structures that generate cells that migrate and differentiate 
(Figure 2b). The cells that give rise to the immature and differentiating cells within neu-
rospheres are CSCs. These cells and their progeny were ablated by the pan-antagonist 
AGN194310 (Figure 2c). It was substantially more effective against two pediatric PNETs 
and a pediatric astrocytoma than ATRA and the RARα-selective agonist AGN195183. Hu-
man fibroblasts and blood mononuclear cells were insensitive to AGN194310. 
 
Figure 2. The pan-RAR antagonist AGN194310 ablates primary cells grown from pediatric primitive neuroectodermal 
tumor biopsies. (a) Metaphase fluorescence in situ hybridization (FISH) of a single cell stained with a probe (red) for the 
chromosome 1 centromere (six copies of chromosome 1 are visible). Scale bar = 100 µm. (b) Primary culture of cells from 
a pediatric primitive neuroectodermal tumor biopsy characterized by a neurosphere-like structure with differentiating 
cells. Scale bar = 100 µm. (c) Dose–response curves of cell viability for two primitive neuroectodermal tumors (i, PNET1) 
and (ii, PNET2) and an astrocytoma (iii, ACT1) following treatment with the pan-RAR antagonist AGN194310, the RARα-
selective agonist AGN195183, or ATRA. Cells were plated into microtitre wells and cell viability determined by measuring 
the level of cellular ATP at day 5. Data are means ± SE of triplicate values from 3 (i), 2 (ii), and 4 (iii) independent experi-
ments. 
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7. The Oncogenic Action of RARγ 
Cell death provoked by the RAR pan-antagonist AGN194310 and the RARγ-selective 
antagonist AGN205728 was found to be mitochondria-dependent and caspase-independ-
ent [74,75]. This process, seen also for retinoid-deprived Jurkat T-cell leukemia cells, is 
termed necroptosis and it occurs via poly-(ADP-ribose) polymerase PARP-1 activation 
[77]. The PARP-1 inhibitor 1,5-dihydroisoquinoline blocked the effects of AGN205728 (un-
published data). PARP-1 ribosylates proteins to change their function leading to mito-
chondrial release of ATP, NAD+ and caspase-independent nucleases that fragment DNA. 
Necroptosis is considered to be a “fail-safe” cell death pathway for apoptosis-resistant 
cells [78], and these data support the notion that active RARγ contributes to blocking this 
process, potentially representing a significant aspect of its oncogenic action. At least 16 
BCL-2 family members control cell survival by mediating apoptosis and/or necroptosis, 
and it is plausible that RARγ may play a role in controlling their expression. Indeed, 
ATRA has been shown to up-regulate expression of the pro-survival BCL2 family mem-
bers MCL-1 and BCL-W [79]. 
Although a clear understanding of the role of RARγ in necroptosis remains to be 
established, the function of a cytosolic form of RARγ seems to be important for TNF-in-
duced cell death in HT-29 colorectal adenocarcinoma cells [80]. When cellular inhibitor of 
apoptosis (cIAP) activity was blocked, RARγ controlled receptor-initiating protein kinase 
1 (RIP1)-initiated cell death by mediating dissociation of RIP1 from TNFR1. Moreover, 
recent studies using Rarg knockout mice and primary squamous cell carcinoma cells have 
shown that loss of RARγ abolishes DNA damage-induced necroptosis [81]. Here, in the 
absence of RAR, the death complex known as the Ripoptosome (RIPK1)/RIPK3) failed to 
form. It is therefore reasonable to speculate that whilst agonizing RARγ leads to its accu-
mulation in the nucleus [67], its antagonism might lead to retention or accumulation in 
the cytoplasm, potentially driving necroptosis. 
8. Concluding Remarks 
The studies described above provide evidence that RARγ functions as a pivotal on-
cogene in the progression of some cases of AML, CRC, CCA, HCC and renal cell cancer. 
There is also evidence to support an oncogenic role in PCa, PNET and ACT. Antagonism 
of RARγ is highly effective in vitro in ablating PCA and BC CSC-like cells, as well as pri-
mary CSCs in PNET and ACT. The finding that RARγ-selective antagonists provoked cell 
death of CSCs via necroptosis represents a novel treatment strategy. The potential of this 
approach is further enhanced by the observation that normal cells seem to be less suscep-
tible to necroptosis following antagonism of RARγ, which might have the benefit of pro-
voking fewer side-effects. While pan-RAR and RARγ-selective antagonism show great 
promise, the results thus far have been obtained in vitro and it is necessary to assess their 
efficacy in vivo. Finally, further work is also required to fully ascertain the mechanisms 
by which RARγ maintains a stem-cell phenotype. Addressing these questions should pro-
vide answers regarding the importance of RARγ in cancer initiation and/or disease pro-
gression. 
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